$56.50
-0.07 (-0.12%)
Open$57.50
Previous Close$56.57
Day High$57.50
Day Low$56.20
52W High$240.00
52W Low$4.35
Volume—
Avg Volume36.0K
Market Cap159.42M
P/E Ratio—
EPS$-53.34
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-20.7% upside
Current
$56.50
$56.50
Target
$44.79
$44.79
$31.89
$44.79 avg
$48.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.25M | 53.02M | 47.19M |
| Net Income | -110,695,812 | 1.91M | 1.39M |
| Profit Margin | -1,079.9% | 3.6% | 2.9% |
| EBITDA | -109,958,977 | 2.67M | 2.51M |
| Free Cash Flow | — | 1.24M | 802.3K |
| Rev Growth | — | +15.8% | -2.9% |
| Debt/Equity | 0.06 | 0.46 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |